Testosterone protects from metabo lic syndrome-associated prostate inflammation: an experimental study in rabbit

Metabolic syndrome (MetS) and benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) are often associated. One of their common denominators is hypogonadism. However, testosterone supplementation is limited by concerns for potential prostatic side effects. The objective was to determine whether MetS-associated prostate alterations are prevented by testosterone supplementation. We used a previously described animal model of MetS, obtained by feeding male rabbits a high-fat diet (HFD) for 12 weeks. Subsets of HFD rabbits were treated with testosterone or with the farnesoid X receptor agonist INT-747. Rabbits fed a standard diet were used as controls. HFD-animals develop hypogonadism and all the MetS features: hyperglycemia, glucose intolerance, dyslipidemia, hypertension, and visceral obesity. In addition, HFD-animals show a prostate inflammation. Immunohistochemical analysis demonstrated that HFD-induced prostate fibrosis, hypoxia, and inflammation. Journal of Endocrinology (2012) 212, 71–84 0022–0795/12/0212–071 q 2012 Society for Endocrinology Printed in Great The mRNA expression of several proinflammatory (IL8, IL6, IL1b, and TNFa), T lymphocyte (CD4, CD8, Tbet, Gata3, and ROR gt), macrophage (TLR2, TLR4, and STAMP2), neutrophil (lactoferrin), inflammation (COX2 and RAGE), and fibrosis/myofibroblast activation (TGFb, SM22a, aSMA, RhoA, and ROCK1/ROCK2) markers was significantly increased in HFD prostate. Testosterone, as well as INT-747, treatment prevented some MetS features, although only testosterone normalized all the HFD-induced prostate alterations. Interestingly, the ratio between testosterone and estradiol plasma level retains a significant, negative, association with all the fibrosis and the majority of inflammatory markers analyzed. These data highlight that testosterone protects rabbit prostate from MetS-induced prostatic hypoxia, fibrosis, and inflammation, which can play a role toward the development/progression of BPH/LUTS. Journal of Endocrinology (2012) 212, 71–84

[1]  L. Adorini,et al.  Farnesoid X receptor activation improves erectile dysfunction in models of metabolic syndrome and diabetes. , 2011, Biochimica et biophysica acta.

[2]  E. Baldi,et al.  Elevated body mass index correlates with higher seminal plasma interleukin 8 levels and ultrasonographic abnormalities of the prostate in men attending an andrology clinic for infertility , 2011, Journal of endocrinological investigation.

[3]  H. Hackstein,et al.  Testosterone Replacement Effectively Inhibits the Development of Experimental Autoimmune Orchitis in Rats: Evidence for a Direct Role of Testosterone on Regulatory T Cell Expansion , 2011, The Journal of Immunology.

[4]  E. Mannucci,et al.  Testosterone, cardiovascular disease and the metabolic syndrome. , 2011, Best practice & research. Clinical endocrinology & metabolism.

[5]  A. Lenzi,et al.  Testosterone and metabolic syndrome: a meta-analysis study. , 2011, The journal of sexual medicine.

[6]  J. S. St. Sauver,et al.  American Journal of Epidemiology Original Contribution Associations between Longitudinal Changes in Serum Estrogen, Testosterone, and Bioavailable Testosterone and Changes in Benign Urologic Outcomes , 2022 .

[7]  Matthew T. Haren,et al.  Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men , 2011, World Journal of Urology.

[8]  C. Roehrborn,et al.  Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action , 2011, Neurourology and urodynamics.

[9]  T. Iwamoto,et al.  Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study , 2011, The aging male : the official journal of the International Society for the Study of the Aging Male.

[10]  R. Donnell.  Benign prostate hyperplasia: a review of the year's progress from bench to clinic , 2011, Current opinion in urology.

[11]  JK Parsons,et al.  Lifestyle factors, benign prostatic hyperplasia, and lower urinary tract symptoms , 2011, Current opinion in urology.

[12]  T. Iwamoto,et al.  Testosterone replacement therapy by testosterone ointment relieves lower urinary tract symptoms in late onset hypogonadism patients , 2010, The aging male : the official journal of the International Society for the Study of the Aging Male.

[13]  E. Abraham,et al.  Toll-like receptors 2 and 4: initiators of non-septic inflammation in critical care medicine? , 2010, Intensive Care Medicine.

[14]  J. Zhao,et al.  Expression of STAMP2 in monocytes associates with cardiovascular alterations , 2010, European journal of clinical investigation.

[15]  E. Barrett-Connor,et al.  Serum sex hormones and the 20‐year risk of lower urinary tract symptoms in community‐dwelling older men , 2010, BJU international.

[16]  W. Paul,et al.  Differentiation of effector CD4 T cell populations (*). , 2010, Annual review of immunology.

[17]  A. Coyle,et al.  HMGB1 and RAGE in inflammation and cancer. , 2010, Annual review of immunology.

[18]  K. McVary,et al.  Lower urinary tract symptoms, obesity and the metabolic syndrome , 2010, Current opinion in urology.

[19]  E. Sarchielli,et al.  Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. , 2009, The journal of sexual medicine.

[20]  M. Zitzmann.  Testosterone deficiency, insulin resistance and the metabolic syndrome , 2009, Nature Reviews Endocrinology.

[21]  G. Forti,et al.  Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. , 2009, International journal of andrology.

[22]  R. Santti,et al.  Inflammation and epithelial alterations in rat prostate: impact of the androgen to oestrogen ratio. , 2009, International journal of andrology.

[23]  L. Adorini,et al.  Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. , 2009, International journal of andrology.

[24]  C. Stournaras,et al.  Control of transforming growth factor β signal transduction by small GTPases , 2009, The FEBS journal.

[25]  C. Dobson,et al.  Amyloid Formation by the Pro-Inflammatory S100A8/A9 Proteins in the Ageing Prostate , 2009, PloS one.

[26]  T. Mizoue,et al.  Lower urinary tract symptoms in relation to lifestyle and medical conditions in Japanese workers , 2009, International journal of urology : official journal of the Japanese Urological Association.

[27]  M. Carini,et al.  Cavernous neurotomy in the rat is associated with the onset of an overt condition of hypogonadism. , 2009, The journal of sexual medicine.

[28]  E. Sarchielli,et al.  The vitamin D receptor agonist elocalcitol inhibits IL‐8‐dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF‐kB pathways , 2009, The Prostate.

[29]  Brice A P Wilson,et al.  Acute inflammatory proteins constitute the organic matrix of prostatic corpora amylacea and calculi in men with prostate cancer , 2009, Proceedings of the National Academy of Sciences.

[30]  L. Gooren,et al.  Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men , 2009, Andrologia.

[31]  I. Thompson,et al.  Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. , 2008, American journal of epidemiology.

[32]  J. Foidart,et al.  Cytokines and chemokines in follicular fluids and potential of the corresponding embryo: the role of granulocyte colony-stimulating factor. , 2008, Human reproduction.

[33]  O. Yokoyama,et al.  Association between lower urinary tract symptoms and serum levels of sex hormones in men. , 2008, Urology.

[34]  S. Krajewski,et al.  Development of diabesity in mice with neuronal deletion of Shp2 tyrosine phosphatase. , 2008, The American journal of pathology.

[35]  James A. Raleigh,et al.  Tuberculous Granulomas Are Hypoxic in Guinea Pigs, Rabbits, and Nonhuman Primates , 2008, Infection and Immunity.

[36]  D. Scherman,et al.  Vascular endothelial growth factor reduced hypoxia-induced death of human myoblasts and improved their engraftment in mouse muscles , 2008, Gene Therapy.

[37]  L. Gooren,et al.  A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. , 2008, Journal of andrology.

[38]  F. Saad,et al.  Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: A pilot study , 2008, The aging male : the official journal of the International Society for the Study of the Aging Male.

[39]  W. Pradidarcheep.  Lower urinary tract symptoms and its potential relation with late-onset hypogonadism , 2008, The aging male : the official journal of the International Society for the Study of the Aging Male.

[40]  S. Çayan,et al.  The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism , 2008, The aging male : the official journal of the International Society for the Study of the Aging Male.

[41]  G. Vannelli,et al.  Effect of sildenafil administration on penile hypoxia induced by cavernous neurotomy in the rat , 2007, International Journal of Impotence Research.

[42]  A. Wolk,et al.  Birth weight, abdominal obesity and the risk of lower urinary tract symptoms in a population based study of Swedish men. , 2007, The Journal of urology.

[43]  Jianfeng Xu,et al.  Inflammation in prostate carcinogenesis , 2007, Nature Reviews Cancer.

[44]  L. Gooren,et al.  An Exploratory Study of the Effects of 12 Month Administration of the Novel Long-Acting Testosterone Undecanoate on Measures of Sexual Function and the Metabolic Syndrome , 2007, Archives of andrology.

[45]  C. Crescioli,et al.  ORIGINAL RESEARCH—BASIC SCIENCE: Effect of Chronic Tadalafil Administration on Penile Hypoxia Induced by Cavernous Neurotomy in the Rat , 2006 .

[46]  D. Legrand,et al.  Lactoferrin: a modulator of immune and inflammatory responses. , 2005, Cellular and molecular life sciences : CMLS.

[47]  L. Vatten,et al.  The prevalence and correlates of urinary tract symptoms in Norwegian men: The HUNT Study , 2005, BJU international.

[48]  R. Roberts,et al.  Serum sex hormones and measures of benign prostatic hyperplasia , 2004, The Prostate.

[49]  U. Heemann,et al.  Association of hypertension with symptoms of benign prostatic hyperplasia. , 2004, The Journal of urology.

[50]  E. Giovannucci,et al.  Associations of obesity with lower urinary tract symptoms and noncancer prostate surgery in the Third National Health and Nutrition Examination Survey. , 2004, American journal of epidemiology.

[51]  P. Gilling,et al.  Long‐term results of high‐power holmium laser vaporization (ablation) of the prostate , 2003, BJU international.

[52]  K. Bennewith,et al.  Orally administered pimonidazole to label hypoxic tumor cells. , 2002, Cancer research.

[53]  R. Voskuhl,et al.  Testosterone Acts Directly on CD4+ T Lymphocytes to Increase IL-10 Production1 , 2001, The Journal of Immunology.

[54]  H. Schumacher,et al.  Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. , 2000, The Journal of urology.

[55]  B. Djavan,et al.  Endocrine status in elderly men with lower urinary tract symptoms: correlation of age, hormonal status, and lower urinary tract function. The Prostate Study Group of the Austrian Society of Urology. , 2000, Urology.

[56]  A. Vandenbark,et al.  Androgens alter the cytokine profile and reduce encephalitogenicity of myelin-reactive T cells. , 1999, Journal of immunology.

[57]  J. Raleigh,et al.  Identification of nonproliferating but viable hypoxic tumor cells in vivo. , 1998, Cancer research.

[58]  S. Lightman,et al.  A protective role for testosterone in adjuvant-induced arthritis. , 1995, British journal of rheumatology.

[59]  G. Arteel,et al.  Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver. , 1995, British Journal of Cancer.

[60]  C. Robinette,et al.  Prolactin mediates estradiol-induced inflammation in the lateral prostate of Wistar rats. , 1993, Endocrinology.

[61]  H. Fox,et al.  Androgen treatment prevents diabetes in nonobese diabetic mice , 1992, The Journal of experimental medicine.

[62]  P. Young,et al.  Beneficial effect of testosterone in the treatment of chronic autoimmune thyroiditis in rats. , 1986, Journal of immunology.

[63]  Mario Maggi,et al.  Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes. , 2011, The journal of sexual medicine.

[64]  A. Traish,et al.  Testosterone deficiency. , 2011, The American journal of medicine.

[65]  M. Carini,et al.  Acute vardenafil administration improves bladder oxygenation in spontaneously hypertensive rats. , 2010, The journal of sexual medicine.

[66]  D. Assimos,et al.  Metabolic syndrome and urologic diseases. , 2010, Reviews in urology.

[67]  K. McVary,et al.  Lower urinary tract symptoms, benign prostatic hyperplasia, and obesity , 2009, Current urology reports.

[68]  J. Nickel.  Prostatic inflammation in benign prostatic hyperplasia - the third component? , 1994, The Canadian journal of urology.

[69]  C. Robinette.  Sex-hormone-induced inflammation and fibromuscular proliferation in the rat lateral prostate. , 1988, The Prostate.